Close Menu

NEW YORK – said today that the US Food and Drug Administration has granted clearance for its smartphone-based albumin-to-creatinine ratio (ACR) test to diagnose chronic kidney disease.

Tel Aviv, Israel-based said that it has also closed a $60 million Series C funding round to accelerate global expansion and product development. Corner Ventures led the funding round, which involved participation by Joy Capital and previous investors Ansonia Holdings, Aleph, and Samsung Next.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.